Ideal weight loss is a never-ending wish for everyone's dreams, but it gets way too slow if done in a healthy way.People around the globe are experimenting with quick ways to shed off their

The Australian Therapeutic Goods Administration (TGA) has updated and aligned safety warnings for people using GLP-1 and dual GIP/GLP-1 receptor agonists. For those not in the know, these are medications like Ozempic, which are used to treat type 2 diabetes and obesity.

Australia's medicines regulator issues a safety warning over the potential risk of suicidal thoughts and behaviours when taking Ozempic-style drugs.

Recommending their long-term use, WHO also said people should undergo intensive behavioural therapy as part of a multi-pronged approach to treating obesity

WHO’s new guidance supports Ozempic-class GLP-1 drugs for obesity treatment, but only alongside behavioural therapy and long-term care, stressing safety concerns, high costs, and the urgent need for equitable global access.

New research suggests that drugs like Ozempic and Wegovy might trigger more than just a slimmer waistline. Many users have reported digestive issues while taking the medications, including nausea, vomiting, constipation and diarrhea, along with headaches, fatigue and changes to the skin.

Health Affairs' Senior Deputy Editor Rob Lott interviews Jihye Han of Brigham and Women's Hospital and Harvard University on her recent paper that takes a closer look at the regulatory treatments for first-in-class drugs and how those differ between the US ...

The amendments introduced in Bill 11, the Health Statutes Amendment Act, 2025 (No. 2), would reflect the government’s commitment to implementing a refocused health care system that recognizes the province’s evolving needs, empowers health care professionals, and supports improved health outcomes for Albertans.